Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 1:52:100518.
doi: 10.1016/j.ahjo.2025.100518. eCollection 2025 Apr.

Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide

Celestine Odigwe  1 , Rajasekhar Mulyala  1 , Haijra Malik  1 , Brent Ruiz  1 , Mariam Riad  1 , Mohammad As Sayiadeh  1 , Sanchitha Honganur  1 , Alexis Parks  1 , Mustafeez Ur Rahman  1 , Nasser Lakkis  1
Affiliations
Review

Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide

Celestine Odigwe et al. Am Heart J Plus. .

Abstract

Semaglutide, a GLP-1 receptor agonist, has emerged as a promising agent in cardiovascular disease management, particularly for patients with obesity and diabetes. Recent studies have demonstrated significant benefits of Semaglutide beyond glycemic control, including reduced major adverse cardiovascular events (MACE), improvements in heart failure symptoms, and weight reduction. Notably, the STEP-HFpEF trial highlighted improved exercise capacity and a reduction in NT-proBNP levels, offering a novel therapeutic pathway for heart failure management. Additionally, Semaglutide has shown anti-inflammatory effects, reducing C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α), thereby mitigating atherosclerotic risks. Moreover, the SELECT trial demonstrated Semaglutide's cardiovascular benefits in non-diabetic, obese patients, suggesting that its effects extend beyond weight loss. These findings represent a potential paradigm shift in cardiovascular risk management, although access and affordability remain key challenges.

Keywords: Atherosclerotic risk; Glucagon-like peptide-1; Heart failure; Inflammation; Semaglutide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Labarre J.F. 1932. Sur les possibilites d’un traitement du diabete par I’incretine.
    1. Nauck M., Stöckmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia. Jan 1986;29(1):46–52. - PubMed
    1. Kreymann B., Ghatei M.A., Williams G., Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. Dec 1987;330(8571):1300–1304. - PubMed
    1. Gasbjerg L.S., Bergmann N.C., Stensen S., Christensen M.B., Rosenkilde M.M., Holst J.J., et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. Mar 2020;125 - PubMed
    1. Jorsal A., Kistorp C., Holmager P., Tougaard R.S., Nielsen R., Hänselmann A., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur. J. Heart Fail. Jan 2017;19(1):69–77. - PubMed

LinkOut - more resources